LPA2 receptor mediates mitogenic signals in human colon cancer cells

American Journal of Physiology - Cell Physiology

Volumn 289, Issue 1 58-1, 2005, Pages

  Yun, C Chris ^a   Sun, Hong ^a   Wang, Dongsheng ^a   Rusovici, Raluca ^a   Castleberry, Amanda ^a   Hall, Randy A ^a   Shim, Hyunsuk ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Na+ H+ exchanger regulatory factor 2

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; INTERLEUKIN 8; LYSOPHOSPHATIDIC ACID; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PERTUSSIS TOXIN; PROTEIN KINASE B; RNA; SODIUM PROTON EXCHANGE PROTEIN; AKT1 PROTEIN, HUMAN; CYTOSKELETON PROTEIN; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHOLIPID; MITOGEN ACTIVATED PROTEIN KINASE KINASE; ONCOPROTEIN; PHOSPHOPROTEIN; PROTEIN SERINE THREONINE KINASE; SMALL INTERFERING RNA; SODIUM HYDROGEN EXCHANGER REGULATORY FACTOR; SODIUM-HYDROGEN EXCHANGER REGULATORY FACTOR;

ARTICLE; CANCER CELL; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MITOGENESIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; BIOSYNTHESIS; CELL STRAIN CACO 2; COLON TUMOR; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; INTESTINE MUCOSA; METABOLISM; MITOSIS; PATHOLOGY;

CACO-2 CELLS; COLONIC NEOPLASMS; CYTOSKELETAL PROTEINS; DRUG INTERACTIONS; ENZYME ACTIVATION; HUMANS; INTERLEUKIN-8; INTESTINAL MUCOSA; LYSOPHOSPHOLIPIDS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOSIS; PHOSPHOPROTEINS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, LYSOPHOSPHATIDIC ACID; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SODIUM-HYDROGEN ANTIPORTER;

EID: 22244473681     PISSN: 03636143     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpcell.00610.2004     Document Type: Article

References (41)

1. An S, Bleu T, Hallmark OG, and Goetzl EJ. Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J Biol Chem 273: 7906-7910, 1998.
2. An S, Dickens MA, Bleu T, Hallmark OG, and Goetzl EJ. Molecular cloning of the human Edg2 protein and its identification as a functional cellular receptor for lysophosphatidic acid. Biochem Biophys Res Commun 231: 619-622, 1997.
3. Contos JJ and Chun J. Genomic characterization of the lysophosphatidic acid receptor gene, lp(A2)/Edg4, and identification of a frameshift mutation in a previously characterized cDNA. Genomics 64: 155-169, 2000.
4. Contos JJ, Ishii I, and Chun J. Lysophosphatidic acid receptors. Mol Pharmacol 58: 1188-1196, 2000.
5. Contos JJA, Ishii I, Fukushima N, Kingsbury MA, Ye X, Kawamura S, Brown JH, and Chun J. Characterization of lpa2 (Edg4) and lpa1/lpa2 (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa2. Mol Cell Biol 22: 6921-6929, 2002.
6. Fang X, Gaudette D, Furui T, Mao M, Estrella V, Eder A, Pustilnik T, Sasagawa T, Lapushin R, Yu S, Jaffe RB, Wiener JR, Erickson JR, and Mills GB. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann NY Acad Sci 905: 188-208, 2000.
7. Fang X, Schummer M, Mao M, Yu S, Tabassam FH, Swaby R, Hasegawa Y, Tanyi JL, LaPushin R, Eder A, Jaffe R, Erickson J, and Mills GB. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta 1582: 257-264, 2002.
8. Fang X, Yu S, Bast RC, Liu S, Xu HJ, Hu SX, LaPushin R, Claret FX, Aggarwal BB, Lu Y, and Mills GB. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian caner cells. J Biol Chem 279: 9653-9661, 2003.
9. Furui T, LaPushin R, Mao M, Khan H, Watt SR, Watt MA, Lu Y, Fang X, Tsutsui S, Siddik ZH, Bast RC, and Mills GB. Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clin Cancer Res 5: 4308-4318, 1999.
10. Gisler SM, Stagljar I, Traebert M, Bacic D, Biber J, and Murer H. Interaction of the type IIa Na/Pi cotransporter with PDZ proteins. J Biol Chem 276: 9206-9213, 2001.
11. Goetzl EJ and An S. Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. FASEB J 12: 1589-1598, 1998.
12. Goetzl EJ, Dolezalova H, Kong Y, Hu YL, Jaffe RB, Kalli KR, and Conover CA. Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer. Cancer Res 59: 5370-5375, 1999.
13. + exchanger regulatory factor family of PDZ proteins. Proc Natl Acad Sci USA 95: 8496-8501, 1998.
14. 2-adrenergic receptor interacts with the Na/H exchanger regulatory factor to control Na/H exchange. Nature 392: 626-630, 1998.
15. Huang MC, Graeler M, Shankar G, Spencer J, and Goetzl EJ. Lysophospholipid mediators of immunity and neoplasia. Biochim Biophys Acta 1582: 161-167, 2002.
16. Huang MC, Lee HY, Yeh CC, Kong Y, Zaloudek CJ, and Goetzl EJ. Induction of protein growth factor systems in the ovaries of transgenic mice overexpressing human type 2 lysophosphatidic acid G protein-coupled receptor (LPA2). Oncogene 23: 122-129, 2004.
17. + exchanger regulatory factor 2. J Biol Chem 275: 16632-16637, 2000.
18. Ishii I, Contos JJ, Fukushima N, and Chun J. Functional comparisons of the lysophosphatidic acid receptors, LP(A1)/VZG-1/EDG-2, LP(A2)/EDG-4, and LP(A3)/EDG-7 in neuronal cell lines using a retrovirus expression system. Mol Pharmacol 58: 895-902, 2000.
19. Li J, Kartha S, Iasvovskaia S, Tan A, Bhat RK, Manaligod JM, Page K, Brasier AR, and Hershenson MB. Regulation of human airway epithelial cell IL-8 expression by MAP kinases. Am J Physiol Lung Cell Mol Physiol 283: L690-L699, 2002.
20. + exchange regulatory factor. J Biol Chem 277: 22925-22933, 2002.
21. + exchanger regulatory factor 2 directs parathyroid hormone 1 receptor signalling. Nature 417: 858-861, 2002.
22. Mills GB, May C, McGill M, Roifman CM, and Mellors A. A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res 48: 1066-1071, 1988.
23. Mills GB and Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 3: 582-591, 2003.
24. Oh YS, Jo NW, Choi JW, Kim HS, Seo SW, Kang KO, Hwang JI, Heo K, Kim SH, Kim YH, Kim IH, Kim JH, Banno Y, Ryu SH, and Suh PG. NHERF2 specifically interacts with LPA2 receptor and defines the specificity and efficiency of receptor-mediated phospholipase C-β3 activation. Mol Cell Biol 24: 5069-5079, 2004.
25. Raghuram V, Hormuth H, and Foskett JK. A kinase-regulated mechanism controls CFTR channel gating by disrupting bivalent PDZ domain interactions. Proc Natl Acad Sci USA 100: 9620-9625, 2003.
26. Rochdi MD and Parent JL. Gαq-coupled receptor internalization specifically induced by Gαq signaling. Regulation by EBP50. J Biol Chem 278: 17827-17837, 2003.
27. Rochdi MD, Watier V, La Madeleine C, Nakata H, Kozasa T, and Parent JL. Regulation of GTP-binding protein αq (Gαq) signaling by the ezrin-radixin-moesin-binding phosphoprotein-50 (EBP50). J Biol Chem 277: 40751-40759, 2002.
28. Sasaki T, Irie-Sasaki J, Jones RG, Oliveira-dos-Santos AJ, Stanford WL, Bolon B, Wakeham A, Itie A, Bouchard D, Kozieradzki I, Joza N, Mak TW, Ohashi PS, Suzuki A, and Penninger JM. Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 287: 1040-1046, 2000.
29. Schulte KM, Beyer A, Kohrer K, Oberhauser S, and Roher HD. Lysophosphatidic acid, a novel lipid growth factor for human thyroid cells: over-expression of the high-affinity receptor edg4 in differentiated thyroid cancer. Int J Cancer 92: 249-256, 2001.
30. Shida D, Kitayama J, Yamaguchi H, Okaji Y, Tsuno NH, Watanabe T, Takuwa Y, and Nagawa H. Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res 63: 1706-1711, 2003.
31. Shida D, Watanabe T, Aoki J, Hama K, Kitayama J, Sonoda H, Kishi Y, Yamaguchi H, Sasaki S, Sako A, Konishi T, Arai H, and Nagawa H. Aberrant expression of lysophosphatidic acid (LPA) receptors in human colorectal cancer. Lab Invest 84: 1352-1362, 2004.
32. Songyang Z, Fanning AS, Fu C, Xu J, Marfatia SM, Chishti AH, Crompton A, Chan AC, Anderson JM, and Cantley LC. Recognition of unique carboxyl-terminal motifs by distinct PDZ domains. Science 275: 73-77, 1997.
33. Wang S, Yue H, Derin RB, Guggino WB, and Li M. Accessory protein facilitated CFTR-CFTR interaction, a molecular mechanism to potentiate the chloride channel activity. Cell 103: 169-179, 2000.
34. Wennstrom S and Downward J. Role of phosphoinositide 3-kinase in activation of Ras and mitogen-activated protein kinase by epidermal growth factor. Mol Cell Biol 19: 4279-4288, 1999.
35. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 12: 375-391, 2001.
36. Xu J, Lai YJ, Lin WC, and Lin FT. TRIP6 enhances lysophosphatidic acid-induced cell migration by interacting with the lysophosphatidic acid 2 receptor. J Biol Chem 279: 10459-10468, 2004.
37. Yart A, Roche S, Wetzker R, Laffargue M, Tonks N, Mayeux P, Chap H, and Raynal P. A function for phosphoinositide 3-kinase beta lipid products in coupling beta gamma to Ras activation in response to lysophosphatidic acid. J Biol Chem 277: 21167-21178, 2002.
38. + exchanger isoform 3 revisited. The roles of SGK1 and NHERF2. J Biol Chem 277: 7676-7683, 2002.
39. + exchanger NHE3 and the cytoskeletal protein ezrin. J Biol Chem 273: 25856-25863, 1998.
40. 3, requires an associated regulatory protein. Proc Natl Acad Sci USA 94: 3010-3015, 1997.
41. Zeilhofer HU and Schorr W. Role of interleukin-8 in neutrophil signaling. Curr Opin Hematol 7: 178-182, 2000.